Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Osakasayama-city, Japan Clinical Trials

A listing of Osakasayama-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (24) clinical trials

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

This is a Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL). HBI 8000 will be administered orally approximately 30 minutes after any regular meal twice a week. There will be 3 ...

Phase

0.0 miles

Learn More »

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate active ulcerative colitis. Participants will be stratified by prior therapeutic treatment and Mayo score at Baseline, and will be randomized 1:1:1 to receive E6007 ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

Approximately 45 participants will be assigned first to pembrolizumab + oxaliplatin + TS-1 combination therapy (Cohort 1), and then 45 participants will be assigned to pembrolizumab + cisplatin + TS-1 combination therapy (Cohort 2).

Phase

0.0 miles

Learn More »

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

This is a multicenter, open-label, Phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) with EZH2 gene mutation.

Phase

0.0 miles

Learn More »

Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

The drug being tested in this study is called Brigatinib. Brigatinib is being tested in patients with ALK-positive NSCLC in order to evaluate efficacy and safety of oral doses of Brigatinib in Japanese patients with ALK-positive NSCLC. The study will enroll approximately 80 participants. Participants will be enrolled in non-randomized ...

Phase

0.0 miles

Learn More »

A Phase 2 Study of Cabozantinib in Japanese Patients With Advanced Hepatocellular Carcinoma

The drug being tested in this study is called Cabozantinib. Cabozantinib is being tested to treat advanced hepatocellular carcinoma in Japanese patients. This study will look at the efficacy and safety of Cabozantinib. The study will enroll approximately 32 patients. Participants will be assigned to Cohort A (at least 17 ...

Phase

0.0 miles

Learn More »

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Some HER-2 breast cancer patients do not respond or build resistance to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these ...

Phase

1.93 miles

Learn More »

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-04/ECHO-305-04)

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death ligand 1 (PD-L1).

Phase

1.93 miles

Learn More »

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Randomization will take place once the consented patient has completed all the necessary baseline procedures and is deemed eligible for study entry. Treatment assignment will be done centrally using a dynamic allocation method (biased coin) via an interactive voice/web response system (IXRS) stratified by: Geographical region (Region 1: Asian [Japan]; ...

Phase

1.93 miles

Learn More »

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.

Phase

1.93 miles

Learn More »